CARDIFF LEXINGTN CORP - $CDIX STOCK NEWS

Cardiff Lexington Corporation (CDIX) announces the opening of a new Nova Ortho and Spine location in Valdosta, Georgia, marking a significant milestone in their growth strategy. This expansion outside of Florida into the broader Southeast region of the United States signifies the company's commitment to providing diagnostic and surgical services for traumatic injury victims. Dr. Kevin Fitzgerald, the newly appointed Managing Director, will oversee the Valdosta location, with plans for further expansion across Georgia and the Southeast.

Cardiff Lexington Corporation (CDIX) appoints Dr. Kevin Fitzgerald, M.D. as Managing Director of Nova Ortho and Spine, their healthcare subsidiary. Dr. Fitzgerald brings over 20 years of medical experience and will oversee day-to-day operations, expansion, patient care, provider production, marketing, and company relations. The company expects accelerated growth with Dr. Fitzgerald's leadership.

Cardiff Lexington Corporation (CDIX) implements a 75,000-to-1 reverse stock split to list its common stock on a national securities exchange. The company's third quarter showed revenue growth, gross margin improvement, and pre-tax net income of approximately $2.0 million. The company is simplifying its capital structure to align share count and public float with its strong operating business, with preferred stockholders committed to converting their shares to common stock. The split aims to strengthen the company's capitalization, support growth, and enhance exposure and liquidity in the public markets.

Cardiff Lexington Corporation (CDIX) appoints Zia Choe as Chief Accounting Officer to support growth strategy. Ms. Choe brings 17 years of finance experience, including M&A due diligence and advisory, to the company. Her role will involve ensuring accurate financial reporting, developing policies aligned with business strategies, and supporting strategic growth initiatives.

Cardiff Lexington Corporation (CDIX) appoints Matthew Shafer as Chief Financial Officer to drive strategic growth initiatives and uplisting to a major U.S. exchange.

Cardiff Lexington Corporation (CDIX) expands Nova Ortho and Spine with a new 1,645 square foot facility in Port St. Lucie, Florida. Dr. Kevin Fitzgerald, with over 20 years of medical experience, will oversee the location. The company now has ten strategically placed locations in Florida, aiming for significant geographic growth.

Cardiff Lexington Corporation (OTC PINK:CDIX) announced the reduction of its convertible debt balance by paying off two convertible promissory notes, totaling $175,000. The company aims to simplify its capital structure to support long-term growth, with the CEO highlighting this payment as an example of their strategy execution.

Cardiff Lexington Corporation (OTC PINK:CDIX) announced a 9.8% growth in its healthcare division, driving a 3.5% consolidated revenue growth to $3.4 million for the third quarter. The company also reported a significant 83% gross profit margin in the healthcare division, leading to a consolidated gross profit margin of 79.6% for the quarter. Operating income increased by 52% to $2.3 million, and net income surged by 415% to $1.98 million. The nine-month period showed similar positive trends, with a 16.2% growth in the healthcare division and a 5.1% consolidated revenue growth to $9.8 million. The company's deliberate focus on higher margin business and disciplined cost containment has resulted in a 247% increase in net income to $2.8 million. Additionally, the balance sheet highlights a 39% increase in total assets to $18.5 million and a 250% increase in stockholders' equity to $975,351. Cardiff Lexington CEO, Alex Cunningham, expressed confidence in the company's sustainable, profitable results and announced preparations for an early 2024 uplisting to a major exchange, along with plans to simplify the capital structure for long-term growth.

Cardiff Lexington Corporation (OTC Pink:CDIX) reported a 20% increase in total assets, a 12.6% increase in revenue, a 19.3% increase in gross profit, and a 1,220.0% increase in net income for the three months ended June 30, 2023, compared to the same period in 2022. For the six months ended June 30, 2023, the company reported a 5.9% increase in revenue, a 12.7% increase in gross profit, and a 149.3% increase in net income, compared to the same period in 2022. The company also announced a new revolving financing agreement to support operational growth.